VaxInnate Corporation today announced that enrollment has commenced in a Phase 1 clinical trial to evaluate VAX2012Q, a recombinant quadrivalent vaccine in development for the prevention of seasonal influenza.
http://ift.tt/1j39Du0
http://ift.tt/1j39Du0
No comments:
Post a Comment